14 December 2023
14 December 2023
Low diversity data reporting rates in DCTs using ePROs point to missed opportunities to embrace patient preferences and racial backgrounds.
Vertex Pharmaceuticals is on track to read out data from three Phase III trials investigating VX-548 in acute pain in Q1 2024.
The Japan-based fund has invested in Fosun Pharma’s Phase III trial testing its triple artemisinin combination drug to accelerate the development and commercialisation.
AOC 1044 was found to be well tolerated with treatment-emergent adverse events observed to be mild to moderate in severity.
Progression-free survival is the primary endpoint of the trial analysing fruquintinib plus sintilimab.
The drug candidate works by preventing the production of sperm in the testes by hindering access to vitamin A.
iECURE is readying study centres for the first-in-human trial and plans to launch it in the first half of next year.
Sunvozertinib was approved in China based on data from the pivotal Phase II WU-KONG6 study in August.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
